Pan Asia Practice

China is a significant part of EGS’s international practice. The Firm’s Corporate and Securities Group represents U.S. companies with operations and activities in China, as well as Chinese enterprises that are listed or do business in the U.S. Our Pan Asia practice has experience in a wide range of China-related matters, and we assist these businesses with strategic growth options, such as private equity financing, mergers and acquisitions, and public offerings. We have frequent and regular involvement in China-related transactions, including Reverse Mergers, Alternative Public Offerings, Private Placements, PIPEs, SPACs, IPOs, and Going Private Transactions. We also have extensive connections to the investment banks, hedge funds, private equity, and venture capital that are actively engaged in transactions related to China. Several of our attorneys that practice in this group are fluent in Mandarin and Cantonese, dialects and English, and we are able to prepare documentation in these languages and liaise with local PRC counsels to address related issues and concerns.

EGS has represented Chinese companies in their acquisition of US assets and businesses.  As part of EGS’ cross border practice the firm has advised Chinese companies on CFIUS and other regulatory issues.

We now represent approximately 15 Chinese companies which are publicly traded in the U.S. In 2018, the Firm’s Pan Asia Practice was the #2 ranked law firm in the world representing issuers/underwriters in IPOs and Secondary Offerings. In 2018, the Firm completed 6 IPOs for China based companies. The Firm has 10 Mandarin speaking attorneys who are all native Chinese. The Firm’s partners that run this Practice have an aggregate of approximately 50 years of experience working in China and are leading experts in this field.